https://www.selleckchem.com/pr....oducts/yap-tead-inhi
Among the 58 cases with POD24, the proportion with transformation differed across groups RCVP (8/25, 32%); RCHOP (16/28, 57.1%); and BR (5/5, 100%). Transformation accounted for 50% (29/58) of POD24 cases whereas only 9 (9/36, 25%) patients had transformation with progression after 24 months. Patients with transformation within 24 months had the worst survival outcome regardless of POD24. Conclusions Transformation negatively impacted survival among FL patients more than POD24 itself. With caution, our findings s
Like
Comment
Share
